A New Approach to Cancer Through Targeted Therapy TransMolecular, Inc.

news and

 publications

press releases | publications and abstracts | in the news

press releases


Press Releases

February 17, 2010
TransMolecular reports annexin A2 is a novel binding partner for TM601

November 5, 2009
TransMolecular presents TM601-002 and TM601-004 Data at SNO 2009

June 17, 2009
TransMolecular's 131I-TM601 Successfully Localizes to Multiple Tumor Types without Targeting Healthy Tissue

June 1, 2009
TransMolecular Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting

May 21, 2009
TransMolecular Announces Presentation of Data Highlighting Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting

May 4, 2009
TransMolecular Presents New Information on Distinct Anti-Angiogenic Mechanism-of-Action of TM601

April 30, 2009
TransMolecular Announces Presentation of Data Confirming Anti-angiogenic Method-of-action TM601 at ARVO Annual Meeting

April 7, 2009
TransMolecular Appoints Robert Radie President and Chief Executive Officer. E. Michael Egan Promoted to Vice Chairman of the Board

December 22, 2008
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma

December 2, 2008
TransMolecular Reaches Special Protocol Agreement with FDA for an 131I-TM601 Phase 3 Trial in Newly Diagnosed Glioblastoma Multiforme Patients

September 29, 2008
Dosing Initiated in TransMolecular's Phase 1/2 Clinical Trial for Intravenous Administration of 131Iodine-TM601 in Patients with Recurrent Malignant Glioma

June 17, 2008
TransMolecular Presents Imaging and Pharmacokinetic Analysis of 131Iodine-TM601 at Society for Nuclear Medicine Meeting

June 2, 2008
TransMolecular Reports Positive Results from Phase 1 Trial of 131Iodine-TM601 in Metastatic Melanoma

May 30, 2008
TransMolecular Initiates Phase 1 Clinical Trial for Unlabeled TM601 in Recurrent Malignant Glioma

April 14, 2008
TransMolecular Unveils First Data on TM601 Anti-Angiogenic Mechanism- of-Action at AACR Annual Meeting

January 7 , 2008
TransMolecular Receives Orphan Drug Designation for Non-radiolabeled TM601 for the Treatment of Malignant Glioma

November 19 , 2007
TransMolecular Reports Positive Phase 2 Data from Study of 131Iodine Radiolabeled TM601 in Recurrent Glioma

October 31, 2007
TransMolecular Reports Positive Phase 1 Trial of 131Iodine Radiolabeled TM601 in Glioma

October 24, 2007
TransMolecular, Inc. Announces Formation of Medical Advisory Board

October 19, 2007
TransMolecular, Inc. Names Morphotek Executive Nicholas C. Nicolaides, Ph.D., Chairman of the Board

View archived press releases